The Latest Cardiac and Vascular News
New data shows CaRi-Heart FAI-Score technology predicts cardiac risk—even in patients with low or zero calcium scores, traditionally considered low-risk CaRi-Heart results from large-scale implementation at five National Health Service (NHS) hospitals in the UK will be presented STAMFORD,…
Medtronic advances pipeline with update on multi-organ denervation study and additional data recently presented at EuroPCR 2025 Medtronic, a global leader in healthcare technology, today announced that it has treated the first patient in its SPYRAL GEMINI Pilot program (including ‘OFF MED’ and ‘ON MED’ studies).* The first patient […]
BAAR, Switzerland–(BUSINESS WIRE)–CorFlow Therapeutics AG (CorFlow), a pioneering company in the field of cardiac care targeting microvascular disease, today announced that the U.S. Food & Drug Administration (FDA) has approved the company’s technology for investigational device exemption (IDE), which allows the pivotal clinical trial to begin at U.S. hospitals. CorFlow will now […]
SANTA MONICA, Calif., July 7, 2025 /PRNewswire/ — Lifeforce, the world’s largest longevity medicine platform, and Toku, a health technology company using AI to translate a single retinal image into real-time biological age and cardiovascular risk scores, have announced a nationwide…
TOKYO, July 7, 2025 /PRNewswire/ — Simplex Quantum, an AI-driven healthcare technology company, is proud to announce that Dr. Marco Perez, Associate Professor of Medicine at Stanford University and a renowned expert in cardiac electrophysiology, has agreed to act as an advisor to Simplex…
COPENHAGEN, Denmark, July 7, 2025 /PRNewswire/ — CathVision ApS, a medical technology company developing electrophysiology solutions for cardiac ablation, announces the market release of ECGenius™ System Version 3.4, introducing multiple software enhancements aimed at improving…
ATLANTA, July 2, 2025 /PRNewswire/ — The MiRus Siegel™ Valve was featured in three podium presentations at the NY Valves meeting last week. Pradeep K. Yadav MD, Piedmont Heart Institute, Atlanta and Raj R. Makkar MD, Cedars Sinai Heart Institute, Los Angeles presented patient case…
PRINCETON, N.J., July 2, 2025 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update on its marketing applications for…
CPT Code for AI-Enabled Cardiac Analysis, Issued by the American Medical Association (AMA), Also Takes Effect July 1, 2025 SAN FRANCISCO, July 1, 2025 /PRNewswire/ — Eko Health, a leader in AI-powered cardiac and pulmonary care, announced a major step forward in expanding access to early…
NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) — Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic heart failure with reduced ejection fraction (HFrEF) and inflammation.
